NOVO — Januar 2025
-
your business over five years is always a nice barometer to work on, and I think we could do something more here from an enterprise value perspective," Levy told Reuters at the JPMorgan health conference in San Francisco.
Catalent, which had sales of $4.38 billion in 2024, will hold its next board meeting in February, according to Levy.
Levy said he expects more drugmakers that currently rely on manufacturers in China and India to look for western service providers with Trump set to return to -
to the White House on Monday, given his America first focus.
Catalent and Thermo Fisher Scientific unit Patheon -- two of the largest contract drug manufacturers based in the U.S. -- could be beneficiaries of such moves.
In addition to his outspoken preference for U.S. manufacturing, Trump has said he will hit China with new tariffs on the first day of his presidency, but Levy did not discuss how that might affect pharmaceuticals.
Levy said Novo Holdings has a venture vehicle with more than 90 -
biopharmaceutical assets that will be "a tremendous pipeline" for Catalent.
He also said he was closely watching lawmaker efforts to pass a bill that would restrict U.S. business with certain Chinese biotechnology companies, including contract drug manufacturer WuXi AppTec.
"Companies like WuXi, for example, they (will) struggle as a result of it," Levy said, "and companies like Catalent will benefit." -
****NOVO NORDISK: HØJDOSIS UDGAVE AF SEMGLUTID VISER VÆGTTAB PÅ 20,7 PCT
-
ja tror folk benhårdt sammenligner med Lilys (bedre nok..)
-
og velbekomme
-
Jeg mener da, at Eli Lillys netop opnåede et vægttab på 20,2%, hvorfor det blev udråbt til bedre end Wegovy. Nu rammer Wegovy så 20,7% i højeste dosis. Men der er igen fokus på Naion øjensygdommen. Det er lidt besynderligt, at det kommer samme dag. Det er som om, enhver god nyhed fra Novo skal neutraliseres af noget andet, også selvom det primært bare er en gentagelse af noget gammelt.
-
****NOVOS OZEMPIC OG WEGOVY INKLUDERET I MEDICARE-PRISFORHANDLINGER I USA
-
enig @craw - intet er åbenbart godt nok pt
-
33% af deltagerne opnåede vægttab på +25% Fra Børsen “Vi er meget glade for at kunne påvise et vægttab på 20,7 pct. og for at se, at 33 pct. af patienterne opnåede mere end 25 pct. vægttab med semaglutid 7,2 milligram, med en sikkerheds- og tolerabilitetsprofil profil, der kan sammenlignes med semaglutid 2,4 milligram,” siger Martin Holst Lange, koncerndirektør med ansvar for udvikling hos Novo Nordisk. "
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind